News | July 30, 2009

Study Refutes Better Renal Safety of Iodixanol Compared to Low-Osmolar Contrast Media

July 30, 2009 – A new study comparing nephrotoxicity of the iso-osmolar contrast medium iodixanol to low-osmolar contrast media (LOCM) found iodixanol shows no reduction in contrast-induced acute kidney injury (CI-AKI) compared to some agents, which may prompt the ACC and AHA to change their current guidelines.

The research shows the more expensive iodixanol (Visipaque, made by GE Healthcare) is better than some of the less expensive LOCM, but is equal to others. The study found a reduction in CI-AKI when iodixanol was compared with ioxaglate and iohexol, but no difference when compared with iopromide (Ultravist, Bayer Healthcare) or ioversol (Optiray, Mallinckrodt).

Earlier studies showed iodixanol offered better kidney protection that LOCM, which led the ACC/AHA to set guidelines recommending iso-osmolar contrast media in patients with chronic kidney disease undergoing angiography. Iodixanol is the only FDA-cleared iso-osmolar agent. However, in addition to the current report, some recent larger randomized trials comparing iodixanol with different types of LOCM have shown no reduction in kidney injury. Experts say new data may prompt the ACC and AHA to review its guidelines.

The study, published in the July issue of JACC Cardiac Interventions, sought to compare the nephrotoxicity of the iso-osmolar contrast medium, iodixanol, to (LOCM). Researchers from the University of Michigan, VA Ann Arbor Healthcare System, and the University of Miami, Fla., looked at 2,763 patients from 16 trials between 1980 to November 2008, which compared the incidence of CI-AKI with either iodixanol or LOCM. Random-effects models were used to calculate summary risk ratios for CI-AKI, need for hemodialysis, and death.

The data shows no significant difference in the incidence of CI-AKI in the iodixanol group than in the LOCM group overall. There was no significant difference in the rates of post-procedure hemodialysis or death. The relative renal safety of LOCM compared with iodixanol may vary based on the specific type of LOCM.

The study authors said a prior meta-analysis suggested that iodixanol was associated with less CI-AKI than LOCM, but this study was limited by ascertainment bias and did not include the most recent randomized controlled trials.

For more information: http://interventions.onlinejacc.org

Related Content

ISMRM Issues Guidelines for MRI Gadolinium Contrast Agents
News | Magnetic Resonance Imaging (MRI)| August 15, 2017
The International Society for Magnetic Resonance in Medicine (ISMRM) has provided new guidance in the use of contrast...
Guerbet Announces Plans to Streamline Contrast Media Portfolio, gadolinium MRI contrast
News | Contrast Media| July 18, 2017
Guerbet recently announced that it will phase out sales throughout the world of two products: Hexabrix (meglumine and...
ACR Offers Revised Contrast Media in Imaging Manual
News | Contrast Media| July 17, 2017
The American College of Radiology (ACR) recently revised its authoritative guide for the safe and effective use of...
Siemens Healthineers Announces First U.S. Install of Artis Pheno Angiography System
News | Angiography| July 05, 2017
Michigan Medicine recently became the first healthcare institution in the United States to install the Artis pheno, the...
Sponsored Content | Videos | Angiography| June 22, 2017
Shimadzu Medical Systems highlighted new features of its Trinias Interventional X-ray line at the America College of
Bayer Arterion contrast Injector used to administer medical imaging contrast for CT scans.

Bayer Healthcare's Arterion contrast injector system.

Feature | Contrast Media| June 19, 2017 | Dave Fornell
Here are several updates in medical imaging...
Sponsored Content | Videos | Angiography| May 03, 2017
Tom Kloetzly, sales and marketing VP for Shimadzu Medical Systems USA, explains the evolution of Shimadzu Corporation...
New Hampshire Hospital Expands Vascular Care with Toshiba Medical's Infinix-I Sky +
News | Angiography| April 27, 2017
Wentworth-Douglass Hospital in Dover, N.H., installed Toshiba Medical’s Infinix-i Sky + angiography system in its...
Overlay Init